Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

clear path for the resubmission of our NDA for NEBIDO(R), our commercial products are performing extremely well in their respective markets, our late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million financing this summer gives us a strong balance sheet.

"After receiving an Approvable letter in June from the FDA on our NDA for NEBIDO, we began planning the course toward resubmission to address FDA's concerns about the quantification of the incidence of serious cough reactions in clinical trials. The NDA contained a single, serious cough reaction in approximately 4,000 injections of NEBIDO. In September, we reached agreement with FDA that submitting additional safety data from ongoing clinical trials in Europe would be appropriate and sufficient to address their concerns. The new data include the results from approximately 10,000 additional injections in Phase IV trials conducted by our partner, Bayer Schering Pharma AG, Germany. The data from these trials has been collected and we believe that there have been no additional cases of serious cough reaction implying an incidence of approximately 1 in 14,000 injections which we believe confirms the rarity of the adverse event. We expect to re-file the NDA by the end of the first calendar quarter of 2009, and FDA will have six months to review the NDA.

"We continue to see strong performance and positive trends for VANTAS(R) (prostate cancer) and SUPPRELIN(R) LA (central precocious puberty). Sales of VANTAS units in the fourth quarter were up 70% over the fourth quarter last year, and we are encouraged by the trends in the first quarter. VANTAS is the only once-yearly treatment in the market and our sales force has done a terrific job of demonstrating the benefits of a long acting product," continued Dr. Cooper.

"Adoption of SUPPRELIN LA in the treatment of central precocious puberty continues
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Chemical Sciences play a significant role in meeting ... safe water, healthy food, and dependable medicine from ... educators, and scientists have a great role in ... for the national development, and to foster research ... emerging Sciences, accelerating with a tremendous speed to ...
(Date:9/19/2014)... crop yields to disease risks, the biological characteristics people ... Just as for heightthe textbook example of a complex ... shaped by multiple genetic and environmental influences, making it ... such genes, geneticists typically mate two individuals that differ ... small mouseand then study their descendents, looking for genes ...
(Date:9/19/2014)... , September 19, 2014 Biotech ... development of emerging drug systems and advanced Laboratory Instrumentation. ... and Company (NYSE: BDX ), Thermo Fisher ... Inc. (NASDAQ: RGDO ), Sangamo Biosciences Inc. ... HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ...
(Date:9/19/2014)... Paul, Minnesota (PRWEB) September 19, 2014 ... from related food industries will gather October 5–8, ... at the Rhode Island Convention Center in Providence, ... will feature the work of food scientists, chemists, ... quality control, and food production management. To date, ...
Breaking Biology Technology:Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3Want to link genes to complex traits? Start with more diversity 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... a.m. EDT, HOPKINTON, Mass., July 23 ... conduct a conference call discussing the,company,s second quarter ... August 6. Kevin Hrusovsky, President and Chief Executive ... the call. Management,will discuss operational and financial results ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") ... synopsis of a proposed Phase 3 clinical study ... and Drug Administration,s (the,"FDA") Division of Cardiovascular and ... the FDA, including a face-to-face,meeting held on April ...
... than a third,of the people who contacted AstraZeneca ... prescription savings programs learned of the programs from ... of more than 12,000,patients., The survey found ... information center regarding prescription savings programs,said they were ...
Cached Biology Technology:Caliper Life Sciences' Second Quarter 2008 Financial Results Conference Call Notice 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
(Date:9/18/2014)... characters, so you might expect that most would have ... some dogs are distinctly more pessimistic than others, research ... research is exciting because it measures positive and negative ... researchers and dog owners an insight into the outlook ... Starling, from the Faculty of Veterinary Science. Her PhD ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2